Top

Published in:

01-12-2013 | Hot Topic

Novel Bone Endocrine Networks Integrating Mineral and Energy Metabolism

Authors: Min Pi, L. Darryl Quarles

Published in: Current Osteoporosis Reports | Issue 4/2013

Abstract

The skeleton is an endocrine organ that regulates energy metabolism through the release of the osteoblast-derived hormone, osteocalcin (Ocn), and phosphate and vitamin D homeostasis through the secretion by osteoblasts and osteocytes of the novel hormone, FGF23 Ocn activates a widely expressed G-protein coupled receptor, GPRC6A, to regulate insulin secretion by pancreatic β−cells, testosterone secretion by testicular Leydig cells, fatty acid metabolism in the liver, and insulin sensitivity of muscle and fat, as well as other functions. FGF23 targets a limited number of tissues, including kidney, parathyroid gland, choroid plexus, and pituitary gland that co-express FGF receptors and α-Klotho complexes. Ectodomain shedding and secretion of a soluble form of Klotho also is purported to act as an anti-ageing hormone. Further elucidation of these novel endocrine networks is likely to lead to new appreciation of the cooperation between various organ systems to regulate phosphate, vitamin D, and energy metabolism.

Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121–45. PMCID: 3571087.PubMedCrossRef

Xiao Z, Zhang S, Magenheimer BS, Luo J, Quarles LD. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem. 2008;283(18):12624–34. PMCID: 2335361.PubMedCrossRef

Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005;20(2):177–84.PubMedCrossRef

Parfitt AM. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone. 2003;33(3):259–63.PubMedCrossRef

Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11(4):219–27. PMCID: 3028072.PubMedCrossRef

Wei W, Dutchak PA, Wang X, Ding X, Bookout AL, Goetz R, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A. 2012;109(8):3143–8. PMCID: 3286969.PubMedCrossRef

Huitema LF, Apschner A, Logister I, Spoorendonk KM, Bussmann J, Hammond CL, et al. Entpd5 is essential for skeletal mineralization and regulates phosphate homeostasis in zebrafish. Proc Natl Acad Sci U S A. 2012;109(52):21372–7. PMCID: 3535636.PubMedCrossRef

Tagliabracci VS, Engel JL, Wen J, Wiley SE, Worby CA, Kinch LN, et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science. 2012;336(6085):1150–3.PubMedCrossRef

Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011;26(4):677–80.PubMedCrossRef

10.

Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J Bone Miner Res. 2011;26(7):1680–3.PubMedCrossRef

11.

Bodine PV, Komm BS. Evidence that conditionally immortalized human osteoblasts express an osteocalcin receptor. Bone. 1999;25(5):535–43.PubMedCrossRef

12.

Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011;26(4):677–80.

13.

Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50(2):568–75. PMCID: 3181267.PubMedCrossRef

14.

Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, et al. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem. 2005;280(48):40201–9.PubMedCrossRef

15.

Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B, Luo J, et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One. 2008;3(12):e3858. PMCID: 2585477.PubMedCrossRef

16.

Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010;285(51):39953–64. PMCID: 3000977.PubMedCrossRef

17.

Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, et al. Endocrine regulation of male fertility by the skeleton. Cell. 2011;144(5):796–809. PMCID: 3052787.PubMedCrossRef

18.

Kuang D, Yao Y, Lam J, Tsushima RG, Hampson DR. Cloning and characterization of a family C orphan G-protein coupled receptor. J Neurochem. 2005;93(2):383–91.PubMedCrossRef

19.

Wellendorph P, Brauner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene. 2004;335:37–46.PubMedCrossRef

20.

Christiansen B, Hansen KB, Wellendorph P, Brauner-Osborne H. Pharmacological characterization of mouse GPRC6A, an L-alpha-amino-acid receptor modulated by divalent cations. Br J Pharmacol. 2007;150(6):798–807. PMCID: 2013871.PubMedCrossRef

21.

Pi M, Zhang L, Lei SF, Huang MZ, Zhu W, Zhang J, et al. Impaired osteoblast function in GPRC6A null mice. J Bone Miner Res. 2010;25(5):1092–102.PubMed

22.

Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010;285(51):39953–64.

23.

Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J Bone Miner Res. 2011;26(7)1680–3.

24.

Pi M, Wu Y, Lenchik NI, Gerling I, Quarles LD. GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets. Endocrinology. 2012;153(10):4608–15. PMCID: 3512028.PubMedCrossRef

25.

Kirmani S, Atkinson EJ, Melton III LJ, Riggs BL, Amin S, Khosla S. Relationship of testosterone and osteocalcin levels during growth. J Bone Miner Res. 2011;26(9):2212–6.PubMedCrossRef

26.

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69. PMCID: 2013746.PubMedCrossRef

27.

Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol. 2009;310(1–2):21–9.PubMedCrossRef

28.

Meigs JB. Epidemiology of the metabolic syndrome, 2002. Am J Manage Care. 2002;8(11 Suppl):S283–92. quiz S93–6.

29.

Iswari S, Colas AE, Karavolas HJ. Binding of 5 alpha-dihydroprogesterone and other progestins to female rat anterior pituitary nuclear extracts. Steroids. 1986;47(2–3):189–203.PubMedCrossRef

30.

Lambert JJ, Belelli D, Hill-Venning C, Peters JA. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci. 1995;16(9):295–303.PubMedCrossRef

31.

Pike CJ, Nguyen TV, Ramsden M, Yao M, Murphy MP, Rosario ER. Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav. 2008;53(5):693–705. PMCID: 2424283.PubMedCrossRef

32.

Chen M, Xu W, Su CL, Lin JF. Testosterone impairs insulin sensitivity in 3T3-L1 adipocytes and the related nongenomic mechanisms. Zhonghua Yi Xue Za Zhi. 2008;88(21):1488–92.PubMed

33.

Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21(6 Pt 2):929–33.PubMedCrossRef

34.

Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension. 2003;42(2):156–60.PubMedCrossRef

35.

Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751–4.PubMedCrossRef

36.

Wang M, Liu F, Hsing AW, Wang X, Shao Q, Qi J, et al. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case–control study in the ChinaPCa consortium. Carcinogenesis. 2012;33(2):356–60.

37.

Long QZ, Du YF, Ding XY, Li X, Song WB, Yang Y, et al. Replication and fine mapping for association of the C2orf43, FOXP4, GPRC6A and RFX6 genes with prostate cancer in the Chinese population. PLoS One. 2012;7(5):e37866. PMCID: 3360662.PubMedCrossRef

38.

Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012;72(4):399–409.

39.

Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, et al. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One. 2011;6(3):e17449. PMCID: 3048873.PubMedCrossRef

40.

Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res. 2005;65(6):2303–13.PubMedCrossRef

41.

Gardner TA, Lee SJ, Lee SD, Li X, Shirakawa T, Kwon DD, et al. Differential expression of osteocalcin during the metastatic progression of prostate cancer. Oncol Rep. 2009;21(4):903–8.PubMed

42.

Nimptsch K, Rohrmann S, Nieters A, Linseisen J. Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case–control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2009;18(1):49–56.PubMedCrossRef

43.

Martin AP, Palumbi SR. Body size, metabolic rate, generation time, and the molecular clock. Proc Natl Acad Sci U S A. 1993;90(9):4087–91. PMCID: 46451.PubMedCrossRef

44.

Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, et al. Meta-analysis of genome-wide association studies in >80,000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123(7):731–8.PubMedCrossRef

45.

Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007;56(3):872–8.PubMedCrossRef

46.

Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–97.PubMedCrossRef

47.

Hwang YC, Jeong IK, Ahn KJ, Chung HY. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int. 2011.

48.

Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94(3):827–32. PMCID: 2681283.PubMedCrossRef

49.

Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278(39):37419–26.PubMedCrossRef

50.

Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291(1):E38–49.PubMedCrossRef

51.

Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 2007;20(4):302–8.PubMedCrossRef

52.

Quarles LD. The bone and beyond: 'Dem bones' are made for more than walking. Nat Med. 2011;17(4):428–30.PubMedCrossRef

53.

Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277(2):494–8.PubMedCrossRef

54.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120–3. PMCID: 2637204.PubMedCrossRef

55.

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–4.PubMedCrossRef

56.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.PubMed

57.

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500–5.PubMedCrossRef

58.

White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF23. Kidney Int. 2001;60(6):2079–86.PubMedCrossRef

59.

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Ren Physiol. 2005;289(5):F1088–95.CrossRef

60.

Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17(5):1305–15.PubMedCrossRef

61.

Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1036–42.PubMedCrossRef

62.

Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117(12):4003–8.PubMed

63.

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.PubMedCrossRef

64.

Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct. 2004;29(4):91–9.PubMedCrossRef

65.

Zhang F, Zhai G, Kato BS, Hart DJ, Hunter D, Spector TD, et al. Association between KLOTHO gene and hand osteoarthritis in a female Caucasian population. Osteoarthr Cartil. 2007;15(6):624–9.

66.

Brown WW, Juppner H, Langman CB, Price H, Farrow EG, White KE, et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's Metaphyseal Chondrodysplasia. J Clin Endocrinol Metab. 2009;94(1):17–20.PubMedCrossRef

67.

Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18(10):2683–8.PubMedCrossRef

68.

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Ren Physiol. 2010;299(4):F882–9.CrossRef

69.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004;44(3):481–7.PubMed

70.

Gutierrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M. (1–34) parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol. 2012;7(1):139–45.PubMedCrossRef

71.

Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150(11):4835–45.PubMedCrossRef

72.

Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone. 2005;36(6):971–7.PubMedCrossRef

73.

Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003;18(7):1227–34.PubMedCrossRef

74.

Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26(2):584–91.

75.

Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286–91. PMCID: 2827593.PubMedCrossRef

76.

Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):257–64.

77.

Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006;69(3):531–7.PubMedCrossRef

78.

Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280(4):2543–9.PubMedCrossRef

79.

Liu S, Tang W, Fang J, Ren J, Li H, Xiao Z, et al. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol. 2009;23(9):1505–18. PMCID: 2737552.PubMedCrossRef

80.

Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131–55. PMCID: 3306265.PubMedCrossRef

81.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408. PMCID: 3204831.PubMedCrossRef

82.

Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010;24(9):3438–50. PMCID: 2923354.PubMedCrossRef

83.

Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010;24(9):3438–50.

84.

Nabeshima Y. Toward a better understanding of Klotho. Sci Aging Knowl Environ. 2006;2006(8):pe11. PMID: 16672727.

85.

Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 2008;27(56):7094–105.PubMedCrossRef

86.

Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317(5839):803–6.PubMedCrossRef

87.

Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92.PubMedCrossRef

88.

Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):2600–8.PubMedCrossRef

89.

Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31(1):219–27.PubMedCrossRef

90.

Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152(10):640–8.PubMedCrossRef

91.

Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481(7381):314–20.PubMedCrossRef

92.

Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D(3) synthesis in leptin-deficient ob/ob mice. J Bone Miner Res. 2010;25(8):1711–23.

93.

Hinoi E, Gao N, Jung DY, Yadav V, Yoshizawa T, Myers Jr MG, et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol. 2008;183(7):1235–42. PMCID: 2606962.PubMedCrossRef

94.

Chateau MT, Araiz C, Descamps S, Galas S. Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in Caenorhabditis elegans. Aging. 2010;2(9):567–81. PMCID: 2984606.PubMed

95.

Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, et al. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest. 2012;122(12):4710–5. PMCID: 3533557.PubMedCrossRef

96.

Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A. 2008;105(9):3455–60. PMCID: 2265125.PubMedCrossRef

97.

Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007;104(50):19796–801. PMCID: 2148378.PubMedCrossRef

98.

Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N, et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int. 2011;89(2):140–50. PMCID: 3135830.PubMedCrossRef

Title: Novel Bone Endocrine Networks Integrating Mineral and Energy Metabolism
Authors: Min Pi
L. Darryl Quarles
Publication date: 01-12-2013
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 4/2013
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-013-0178-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Novel Bone Endocrine Networks Integrating Mineral and Energy Metabolism

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Evaluation and Management of the Premenopausal Woman with Low BMD

Idiopathic Osteoporosis in Men

Osteoporosis after Stem Cell Transplantation

Fracture Liaison Services in an Open System: How was it Done? What Were the Barriers and How Were They Overcome?

Effects of Radiation on Bone

Fracture Liaison Services in the United Kingdom